Breaking News, Collaborations & Alliances

BioMed X Launches Collaboration with Daiichi Sankyo to Explore New Approaches in Cancer Treatment

Aims to leverage advances in multi-functional biologics to develop new therapies that can engage multiple targets simultaneously within the tumor microenvironment.

Author Image

By: Charlie Sternberg

Associate Editor

BioMed X, an independent biomedical research institute based in Germany, has launched a new collaboration with Daiichi Sankyo Co., Ltd.—marking the start of a new initiative to explore innovative approaches in cancer treatment using multi-specific biologics. The project, entitled “New Strategies for Targeting of Solid Tumors with Multi-Specific Biologics (MTT; Multi-Specific Targeting of Tumors),” will be hosted at the BioMed X Institute in Heidelberg. The partnership aims to leverage the ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics